Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Abstract Background Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and over...

Full description

Bibliographic Details
Main Authors: Thanaporn Bussabawalai, Kittiphong Thiboonboon, Yot Teerawattananon
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-utility analysis
Adjuvant imatinib
Recurrence
Gastrointestinal stromal tumour
GIST
Online Access:http://link.springer.com/article/10.1186/s12962-018-0169-9

Internet

http://link.springer.com/article/10.1186/s12962-018-0169-9

Similar Items